Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China

Current Medical Research and Opinion

Volumn 26, Issue 6, 2010, Pages 1443-1449

  Hu, Bijie ^a   Ye, Huifeng ^b   Xu, Yingchun ^c   Ni, Yuxing ^d   Hu, Yunjian ^e   Yu, Yunsong ^f   Huang, Zhenfei ^g   Ma, Larry ^h  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e BEIJING HOSPITAL   (China)

^f ZHEJIANG UNIVERSITY   (China)

^g Medical Department   (China)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

China; Clinical outcome; Community acquired infection; Economic outcome; Extended spectrum beta lactamase (ESBL)

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE;

ABDOMINAL INFECTION; ADULT; ARTICLE; CHINA; COMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COST; ECONOMIC EVALUATION; ESCHERICHIA COLI; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RETROSPECTIVE STUDY;

ABDOMEN; ADULT; AGED; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CHINA; COMMUNITY-ACQUIRED INFECTIONS; COSTS AND COST ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA; KLEBSIELLA INFECTIONS; MALE; MEDICAL AUDIT; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77952536690     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003769068     Document Type: Article

References (33)

1. Schwaber MJ, Navon-Venezia S, Kaye KS, et al. Clinical and economic impact of bacteremia with extended-spectrum-jß-lactamase-producing enterobacter-iaceae. Antimicrob Agents Chemother 2006;50:1257-1262
2. Pfaller M, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum jß-lactamases. Clin Infect Dis 2006;42(Suppl. 4):S153-63
3. Ramphal R, Ambrose PG. Extended-spectrum jß-lactamases and clinical outcomes: current data. Clin Infect Dis 2006;42:S164-72
4. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum jß-lactamase-and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005;53:257-264
5. Kaye K, Engemann J, Fraimow H, et al. Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms and clinical management. Infect Dis Clin North Am 2004;18:467-511
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. M100S15. Wayne, PA, USA: Clinical and Laboratory Standards Institute, 2005
7. Bush K. New beta-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001;32:1085-1089
8. Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1991;35:1697-1704
9. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003;6:1433-1437
10. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring. Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-973
11. Hsueh PR, Snyder TA, Dinubile MJ, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2006;28:238-243
12. Chow J, Satishchandran V, Snyder T, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt) 2005;6:439-448
13. Baquero F, Hsueh PR, Paterson DL, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect 2009;10: 99-104
14. Bradford P. Extended-spectrum jβ-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-951
15. Wiener J, Quinn JP, Bradford P, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:563-564
16. Apisarnthanarak A, Kiratisin P, Saifon P, et al. Clinical and molecular epidemiology of community-onset, extended-spectrum jβ-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am J Infect Control 2007;35:606-612
17. Rodriguez-Bano J, Alcala J, Cisnerosn J, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008;168:1897-1902
18. Tian SF, Chen BY, Chu YZ, et al. Prevalence of rectal carriage of extended-spectrum jß-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol 2008;54:781-785
19. Ben-Ami R, SchwaberM, Navon-Venezia S, etal. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 2006;42:925-934
20. Moor C, Roberts S, Simmons G, et al. Extended-spectrum beta-lactamase (ESBL)-producing enterobacteria: factors associated with infection in the community setting, Auckland, New Zealand. J Hosp Infect 2008;68:355-362
21. Pitout J, Nordmann P, Laupland K, et al. Emergence of Enterobacteriaceae producing extended-spectrum jß-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52-59
22. Zhang Y, Zhu D, Hu F. Changes of antimicrobial resistance among clinical isolates of Escherichia coli in Shanghai 1990-2000. Natl Med J China 2006;86:12-16 (Pubitemid 43125202)
23. Wang F, on behalf of CHINET Working Group. CHINET 2006 surveillance of bacterial resistance in China. Chin J Infect Chemother 2008;8:1-9
24. Wang H, Chen M, Ni Y, et al. Antimicrobial resistance analysis among nos-ocomial Gram-negative bacilli from 10 teaching hospitals in China in 2006. Chin J Lab Med 2008;31:623-627
25. Yang QW, Xu YC, Chen MJ, et al. Surveillance of antimicrobial resistance among nosocomial Gram-negative pathogens from 15 teaching hospitals in China in 2005. Natl Med J China 2007;87:2753-2758
26. Kang CI, Kim SH, Kim DM, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumonia. Infect Control Hosp Epidemiol 2004;25:860-867
27. Kang CI, KimSH, ParkWB, etal. Clinical outcome of bacteremic spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumonia. Korean J Intern Med 2004; 19:160-164
28. Lee SY, Kotapati S, Kuti JL, et al. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006;27:1226-1232
29. Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-1171
30. Moland ES, Black JA, Ourada J, et al. Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals. Antimicrob Agents Chemother 2002;46:3837-3842
31. Lee SY, Kuti, JL, Nicolau DPl. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. J Infect 2007;54:463-468
32. Ko WC, Hsueh PR. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdom-inal infections in the Asia/Pacific region: data from the Smart Study 2002-2006. J Infect 2009;59:95-103
33. Hawser SP, Bouchillon SK, Hoban DJ, et al. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 2009;53:3280-3284